World's Best Scientists 2026 revealed!
Bernardo A. Pons-Estel

Bernardo A. Pons-Estel

D-Index & Metrics

Biology and Biochemistry

D-Index
60
Citations
15203
World Ranking
11824
National Ranking
5086

Bernardo A. Pons-Estel publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Bernardo A. Pons-Estel sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 165 publications — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Bernardo A. Pons-Estel D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Bernardo A. Pons-Estel sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 60 D-Index — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Bernardo A. Pons-Estel is affiliated with the Allegheny Health Network in the United States and has produced extensive research in the field of medicine, with a particular focus on rheumatology. Their academic work spans multiple subfields, including immunology, pathology and forensic medicine, hematology, and neurology.

Their primary research topics cover a range of systemic and autoimmune diseases. The main areas of study include:

  • Systemic Lupus Erythematosus Research
  • Atherosclerosis and Cardiovascular Diseases
  • Rheumatoid Arthritis Research and Therapies
  • Systemic Sclerosis and Related Diseases
  • Autoimmune and Inflammatory Disorders Research
  • Peripheral Neuropathies and Disorders
  • Monoclonal and Polyclonal Antibodies Research

Pons-Estel's publications appear frequently in several leading journals and venues, demonstrating sustained activity in the rheumatology field. These publication venues include:

  • Annals of the Rheumatic Diseases
  • Lupus
  • Revista Argentina de Reumatología
  • The Journal of Rheumatology
  • JCR Journal of Clinical Rheumatology

Among recent papers associated with the broader research community in this area, notable articles include:

  • "EULAR recommendations for the management of systemic lupus erythematosus: 2023 update" (2023), published in Annals of the Rheumatic Diseases
  • "Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial" (2020), published in The Lancet Respiratory Medicine
  • "2021 DORIS definition of remission in SLE: final recommendations from an international task force" (2021), published in Lupus Science & Medicine
  • "Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies" (2021), published in Lupus Science & Medicine
  • "Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review" (2021), published in Lupus Science & Medicine

The scientist has frequently collaborated with other researchers in the field. The most common coauthors include:

  • Guillermo Pons-Estel
  • Rosana Quintana
  • Manuel F. Ugarte-Gil
  • Graciela S. Alarcón
  • Mercedes García

This body of work collectively contributes to understanding systemic autoimmune diseases and related conditions in rheumatology, underlining a multidisciplinary approach across immunology, pathology, and cardiovascular research within clinical and experimental medicine.

Best Publications

  • Human polymorphism at microRNAs and microRNA target sites.

    Liuqing Yang;Chunru Lin;Chunyu Jin;Joy C. Yang

  • A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus.

    Robert R. Graham;Robert R. Graham;Sergey V. Kozyrev;Emily C. Baechler;M. V.Prasad Linga Reddy

  • Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.

    Dinesh Khanna;Celia J F Lin;Daniel E Furst;Jonathan Goldin

  • Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus

    Sergey V. Kozyrev;Anna Karin Abelson;Jerome Wojcik;Ammar Zaghlool

  • Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.

    Paul Emery;Roy M. Fleischmann;Larry W. Moreland;Elizabeth C. Hsia

  • Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort.

    Donato Alarcón‐Segovia;Marta E. Alarcón‐Riquelme;Mario H. Cardiel;Francisco Caeiro

  • The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among "Hispanics".

    Bernardo A Pons-Estel;Luis J Catoggio;Mario H Cardiel;Enrique R Soriano

  • The Tumor-Necrosis-Factor Receptor–Associated Periodic Syndrome: New Mutations in TNFRSF1A, Ancestral Origins, Genotype-Phenotype Studies, and Evidence for Further Genetic Heterogeneity of Periodic Fevers

    Ivona Aksentijevich;Jérôme Galon;Miguel Soares;Elizabeth Mansfield

  • Transancestral mapping and genetic load in systemic lupus erythematosus

    Carl D. Langefeld;Hannah C. Ainsworth;Deborah S. Cunninghame Graham;Jennifer A. Kelly

  • Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort

    B. Namjou;P. H. Kothari;J. A. Kelly;S. B. Glenn

  • Genomic Insights into the Ancestry and Demographic History of South America

    Julian R. Homburger;Andrés Moreno-Estrada;Andrés Moreno-Estrada;Christopher R. Gignoux;Dominic Nelson

  • Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus

    Indra Adrianto;Feng Wen;Amanda Templeton;Graham B. Wiley

  • Association of systemic lupus erythematosus with decreased immunosuppressive potential of the IgG glycome

    Frano Vučković;Jasminka Krištić;Ivan Gudelj;Maria Teruel

  • Association of Genetic Variants in Complement Factor H and Factor H-Related Genes with Systemic Lupus Erythematosus Susceptibility

    Jian Zhao;Hui Wu;Melanie Khosravi;Huijuan Cui

  • 2021 DORIS definition of remission in SLE: final recommendations from an international task force.

    Ronald F van Vollenhoven;George Bertsias;Andrea Doria;David Isenberg

  • Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as Susceptibility Loci for Systemic Lupus Erythematosus in a Large-Scale Multiracial Replication Study

    Christopher J. Lessard;Christopher J. Lessard;Christopher J. Lessard;Indra Adrianto;John A. Ice;Graham B. Wiley

  • Antimalarial Treatment May Have a Time-Dependent Effect on Lupus Survival: Data From a Multinational Latin American Inception Cohort

    Samuel K. Shinjo;Eloísa Bonfá;Daniel Wojdyla;Eduardo F. Borba

  • Male systemic lupus erythematosus in a Latin-American inception cohort of 1214 patients.

    M A Garcia;J C Marcos;A I Marcos;B A Pons-Estel

  • STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk

    Anna-Karin Abelson;Angélica Maria Delgado-Vega;Sergey V Kozyrev;Elena Sánchez

  • Unraveling multiple MHC gene associations with systemic lupus erythematosus: model choice indicates a role for HLA alleles and non-HLA genes in Europeans.

    David L. Morris;Kimberly E. Taylor;Michelle M.A. Fernando;Joanne Nititham

Frequent Co-Authors

Marta E. Alarcón-Riquelme
Marta E. Alarcón-Riquelme University of Granada
Graciela S. Alarcón
Graciela S. Alarcón University of Alabama at Birmingham
John B. Harley
John B. Harley United States Department of Veterans Affairs
Kenneth M. Kaufman
Kenneth M. Kaufman Cincinnati Children's Hospital Medical Center
Judith A. James
Judith A. James Oklahoma Medical Research Foundation
R. Hal Scofield
R. Hal Scofield University of Oklahoma Health Sciences Center
Jennifer A. Kelly
Jennifer A. Kelly Oklahoma Medical Research Foundation
Patrick M. Gaffney
Patrick M. Gaffney Oklahoma Medical Research Foundation
Timothy J. Vyse
Timothy J. Vyse King's College London
Carl D. Langefeld
Carl D. Langefeld Wake Forest University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The fields of Biology and Biochemistry open doors to many dynamic online degree and career opportunities. For instance, students interested in applying biochemical knowledge to health and wellness might consider pursuing an online degree in nutrition, which prepares graduates for roles in dietetics, food science, or public health.

Those aiming to move into healthcare administration can explore the number of cahme accredited mha programs available online. These programs provide the skills needed for leadership roles in hospitals, clinics, and healthcare systems.

Science graduates interested in nursing leadership can consider earning a dnp online no clinicals degree. This advanced program is designed for working professionals seeking to elevate their impact without mandatory clinical hours.

Further academic growth is possible with an online phd in healthcare management. This qualification leads to opportunities in research, policy-making, and higher education.

Exploring these online options makes it easier than ever for Biology and Biochemistry students to advance their expertise and expand their career choices in healthcare and related industries.

Best Scientists Citing Bernardo A. Pons-Estel

Trending Scientists

Recently Published Articles